Takahashi, Masato http://orcid.org/0000-0002-6641-9598
Inoue, Kenichi
Mukai, Hirofumi
Yamanaka, Takashi
Egawa, Chiyomi
Miyoshi, Yasuo
Sakata, Yukinori
Muramoto, Kenzo
Ikezawa, Hiroki
Matsuoka, Toshiyuki
Tsurutani, Junji
Funding for this research was provided by:
Eisai Co., Ltd.
Article History
Received: 24 November 2020
Accepted: 22 February 2021
First Online: 7 March 2021
Declarations
:
: M. Takahashi received honoraria from AstraZeneca, Eli Lilly, and Pfizer; and received research funding from Taiho and Kyowa Hakko Kirin. K. Inoue received grants from Novartis, Pfizer, Chugai, Daiichi-Sankyo, Parexel/Puma Biotechnology, MSD, Bayer, Eli Lilly, AstraZeneca, Sanofi, and Eisai; and received personal fees from Eisai, Chugai, Pfizer, and Eli Lilly. H. Mukai received grants from Eisai, Daiichi Sankyo, Pfizer, Japanese Government, and Nippon Kayaku; and personal fees from Eisai, Daiichi Sankyo, Pfizer, AstraZeneca, Taiho, and Takeda. T. Yamanaka received honoraria from Chugai, Eisai, Daiichi-Sankyo, Novartis, Pfizer, Kyowa-Kirin, and Eli Lilly. C. Egawa declares no conflicts of interest. Y. Miyoshi received grants from Eisai, Chugai, MSD, Kyowa-Kirin, Eli Lilly, and Taiho; and personal fees from Eisai, Chugai, AstraZeneca, Eli Lilly, and Pfizer. Y. Sakata, K. Muramoto, H. Ikezawa, and T. Matsuoka are employees of Eisai Co., Ltd. J. Tsurutani is an adviser of Eisai Co., Ltd., Asahi Kasei Corporation, and Daiichi Sankyo; received honoraria from Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Roche Diagnostics K.K., Novartis Pharma, AstraZeneca K.K., and Kyowa-Kirin; received research funds from Eisai Co., Ltd. and Taiho Pharmaceutical Co., Ltd.; and his institution received donations from Eisai, Chugai, Daiichi-Sankyo, Nihonkayaku, Eli Lilly, Boehringer Ingelheim, MSD, and Pfizer.
: This study was conducted in accordance with the Declaration of Helsinki and Japanese Good Post-Marketing Study Practice (GPSP), which is an authorized standard for post-marketing surveillance. GPSP does not require approval from the institutional review boards of each institution. However, in practice, some institutions may have obtained approval when deemed necessary.
: GPSP does not require approval from each institution’s institutional review board or informed consent from the participating patients. Therefore, obtaining informed consent was not mandatory for this type of study. However, in some institutions, informed consent may have been obtained from participants.